ARL-17477 dihydrochloride hydrate

SIGMA/SML0178 - ≥98% (HPLC)

Synonym: N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate

CAS Number: 866914-87-6 (anhydrous)
Empirical Formula (Hill Notation): C₂₀H₂₀ClN₃S·2HCl · xH₂O
Molecular Weight: 442.83 (anhydrous basis)
MDL Number: MFCD21608518
Linear Formula: C₂₀H₂₀ClN₃S·2HCl · xH₂O
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-SML0178-5MG	5 mg	$163.00 1/EA	Add To Favorites
45-SML0178-25MG	25 mg	$0.00 1/EA CALL FOR PRICE	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
InChI key	QOPATWWWZNTSQF-UHFFFAOYSA-N
originator	AstraZeneca
Quality Level	100
SMILES string	O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
solubility	H₂O: ≥5 mg/mL
storage condition	desiccated
storage temp.	2-8°C

Application:	ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.
Biochem/physiol Actions:	ARL-17477 is an nNOS specific inhibitor. The IC₅₀ against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.
Features and Benefits:	This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	5, 25 mg in glass bottle

Symbol	GHS07
Signal word	Warning
Hazard statements	H302 - H319
Precautionary statements	P301 + P312 + P330 - P305 + P351 + P338
Hazard Codes	Xn
Risk Statements	22-36
Safety Statements	26
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352200

To Order From a Quote